Saturday, Jun 15, 2024
Update At 14:00    USD/EUR 0,92  ↑+0.0002        USD/JPY 151,69  ↑+0.174        USD/KRW 1.347,35  ↑+6.1        EUR/JPY 164,16  ↑+0.143        Crude Oil 85,49  ↓-0.76        Asia Dow 3.838,83  ↑+1.8        TSE 1.833,50  ↑+4.5        Japan: Nikkei 225 40.846,59  ↑+448.56        S. Korea: KOSPI 2.756,23  ↓-0.86        China: Shanghai Composite 3.015,74  ↓-15.745        Hong Kong: Hang Seng 16.512,92  ↓-105.4        Singapore: Straits Times 3,27  ↑+0.018        DJIA 22,58  ↓-0.23        Nasdaq Composite 16.315,70  ↓-68.769        S&P 500 5.203,58  ↓-14.61        Russell 2000 2.070,16  ↓-4.0003        Stoxx Euro 50 5.064,18  ↑+19.99        Stoxx Europe 600 511,09  ↑+1.23        Germany: DAX 18.384,35  ↑+123.04        UK: FTSE 100 7.930,96  ↑+13.39        Spain: IBEX 35 10.991,50  ↑+39.3        France: CAC 40 8.184,75  ↑+33.15        

Shining a light on cancer care: Solasia Pharma’s dedication to providing quality pharmaceuticals

Article - September 28, 2023

From Sancuso to Darvias - a journey of developing high-quality pharmaceuticals for cancer patients.

“As our company name suggests, our mission is to continue to be the sun that illuminates the future of people facing cancer.”

Few products are as closely tied to the well-being of patients as the pharmaceuticals targeting cancer. One of the companies driving innovation in drugs that manage the symptoms and adverse reactions of oncological medicines and chemotherapies is Japan’s Solasia.

Since launching its first product, Sancuso, in 2018, the company has continued to develop medicines that improve its patient’s lives.

The latest pipeline in Solasia’s product list is SP-04, which is designed to prevent chemotherapy-induced peripheral neuropathy (CIPN). SP-04 mimics one of the enzymes responsible for reducing ROS in the body, a new mode of action not found in existing medicines. If approved, SP-04 would be the first drug to prevent CIPN, and company president Yoshihiro Arai reveals that Solasia is “in the process of evaluation of the compound in the animal model of CIPN caused by the target chemotherapy”.

The company is also conducting joint research and development of nucleic acid medicine for the treatment of peritoneal dissemination with the GeneCare Research Institute, a Japanese biotechnology firm.

This joint development will target the RECQL1-siRNA, which is believed to have a novel mechanism of action to induce cell death by selectively suppressing the expression of the DNA repair enzyme helicase RECQL1, which is found to be overexpressed in cancer cells.

In multiple pharmacological studies, the product has been shown to suppress the growth of various types of cancer and prolong survival in animal models of peritoneal dissemination associated with advanced-stage ovarian or gastric cancer.

Solasia’s marketed drug Darvias has shown great potential for the treatment of peripheral T-cell lymphoma and the Named Patient Program process has been started in Europe, India and China, with South America to follow shortly.

The potential of Darvias’ unique targeting of the mitochondria in the cell makes it particularly attractive, and Mr. Arai says Solasia is always on the lookout and exploring licensing opportunities to collaborate with potential partners, especially in the Asian markets.

From Sancuso to Darvias - Solasia continues its journey of developing high-quality pharmaceuticals for cancer patients.